nucala mepolizumab - Search News

News

Nucala, GSK and FDA

FDA Approves GSK's Nucala for Expanded Use in COPD

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth indication. The drug is now cleared to treat certain patients with chronic obstructive pulmonary disease (COPD).

Pharmabiz · 4h

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the

The Manhattan Mercury · 12h

FDA Approves Nucala for Chronic Obstructive Pulmonary Disease

The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive

The American Journal of Managed Care1d

FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

ATS 2025: Nucala reduces COPD exacerbations, regardless of severe event history

Patients were randomised 1:1 to receive Nucala 100mg or placebo subcutaneously every four weeks in addition to standard ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

Nucala, GSK and FDA

Trending now